Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients

Lorenzo Cavagna1, Veronica Codullo, Stefano Ghio

  • 1aDivision of Rheumatology bDepartment of Cardiology, University and IRCCS Foundation Policlinico S. Matteo, Pavia cEpidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

Medicine
|September 30, 2016
PubMed

Insights

A significant number of patients initially diagnosed with idiopathic pulmonary arterial hypertension (PAH) actually have undiagnosed connective tissue diseases (CTDs). Early rheumatological assessment is crucial, particularly for those with Raynaud phenomenon, due to the poor prognosis associated with Systemic Sclerosis-PAH.

Area of Science:

  • Cardiology
  • Rheumatology
  • Pulmonology

Background:

  • Pulmonary arterial hypertension (PAH) subgroups, especially those linked to connective tissue diseases (CTDs), exhibit distinct clinical and prognostic profiles.
  • Accurate etiological diagnosis is essential for appropriate management of PAH patients.

Purpose of the Study:

  • To determine the frequency of previously undiagnosed CTDs in patients suspected of having idiopathic PAH (iPAH).
  • To evaluate the prognostic impact of CTDs in PAH patients.

Main Methods:

  • Consecutive PAH patients without prior rheumatological assessment underwent comprehensive CTD evaluation (clinical, laboratory, instrumental).
  • Survival analysis was performed for different etiological subgroups (iPAH, CTD-PAH, Systemic Sclerosis-PAH).

Main Results:

  • 34.7% of the iPAH cohort were diagnosed with CTD-PAH.
  • Antinuclear antibody (ANA) positivity showed high sensitivity and specificity for CTD-PAH.
  • Raynaud phenomenon (RP) was highly specific for Systemic Sclerosis (SSc)-PAH.
  • Mortality was significantly higher in SSc-PAH patients compared to iPAH patients.

Conclusions:

  • A substantial prevalence of undiagnosed CTDs exists within the iPAH population.
  • Rheumatological assessment is vital for PAH patients, especially those presenting with RP.
  • Systemic Sclerosis-associated PAH carries a particularly unfavorable prognosis, underscoring the need for early identification and management.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
766
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
580
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
549
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
682
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532